Satraplatin

Satraplatin is an orally bioavailable platinum(IV) complex and the first oral platinum-based anticancer agent to advance to Phase III clinical trials. Mediocon Inc supplies pharmaceutical-grade Satraplatin conforming to IP / BP / EP / USP specifications from our GMP-certified facility in Aurangabad, Maharashtra, India.

Satraplatin forms platinum-DNA adducts that inhibit DNA replication and transcription in rapidly dividing cancer cells. Its oral bioavailability offers significant practical advantages over intravenous platinum agents.

Key Features

• High-purity pharmaceutical grade API
• IP / BP / EP / USP compliant
• Full CoA and MSDS documentation
• GMP certified manufacturing facility

Applications

• Prostate cancer chemotherapy
• Oral platinum-based oncology
• Cisplatin-resistant cancer treatment
• Urological oncology R&D

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings

Parameter	Specification
Assay	NLT 98.0%
Loss on Drying	NMT 0.5%
Heavy Metals	NMT 20 ppm
Residue on Ignition	NMT 0.1%
Microbial Limits	Complies with pharmacopoeia
Identification	IR, HPLC Compliant
Mfg Date	MAR 2025
Exp Date	FEB 2030
Packing	25 kg HDPE drums / as per requirement